Literature DB >> 18836414

Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy.

T H Williamson1, R Rajput, D A H Laidlaw, B Mokete.   

Abstract

PURPOSE: To describe the management of vitreoretinal complications of sickle cell retinopathy.
DESIGN: A retrospective interventional case series.
METHODS: Review of an electronic patient record and clinical notes of 27 patients with vitreoretinal complications of sickle retinopathy.
RESULTS: Six male patients and 21 female patients presented with a mean age of 41 years (range 28-67), 12 left eyes and 16 right eyes. The mean follow-up was 15.5 months (range: 3-60). Two patients were SS, and the remainders were doubly heterozygous (SC). In all, 10 were observed without surgery- three with vitreous haemorrhage, four tractional retinal detachments (TRD), and three rhegmatogenous retinal detachments (RRD). Two patients demonstrated spontaneous flattening of the retina- one RRD and one TRD. Eighteen eyes had pars plana vitrectomies (PPVs)- seven with vitreous haemorrhage, three RRD, three TRD, three ERM (one bilateral), and two macular holes. In all, 15 patients (83%) had improved vision postoperatively. The mean logMar preoperative visual acuity was 1.07 (Snellen equivalent 6/70), SD 0.62 was significantly improved postoperatively (mean 0.42 (6/15), SD 0.48, P=0.001).
CONCLUSIONS: Sickle retinopathy occasionally presents with vitreoretinal complications. These can often be observed and may spontaneously regress. If surgery is required eyes respond to vitrectomy procedures with segmentation of sea fan proliferation.

Entities:  

Mesh:

Year:  2008        PMID: 18836414     DOI: 10.1038/eye.2008.296

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  9 in total

Review 1.  New Ways to Detect Pediatric Sickle Cell Retinopathy: A Comprehensive Review.

Authors:  Daniel A Pahl; Nancy S Green; Monica Bhatia; Royce W S Chen
Journal:  J Pediatr Hematol Oncol       Date:  2017-11       Impact factor: 1.289

2.  A comparison of 23-gauge and 20-gauge vitrectomy for proliferative sickle cell retinopathy - clinical outcomes and surgical management.

Authors:  Jason Ho; Anna Grabowska; Marta Ugarte; Mahiul Mk Muqit
Journal:  Eye (Lond)       Date:  2018-05-22       Impact factor: 3.775

3.  Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series.

Authors:  Royce W S Chen; Harry W Flynn; Wen-Hsiang Lee; D Wilkin Parke; Ryan F Isom; Janet L Davis; William E Smiddy
Journal:  Am J Ophthalmol       Date:  2013-12-31       Impact factor: 5.258

4.  Action on sickle cell retinopathy: the time is now.

Authors:  Christiana Dinah; Brigit Greystoke; Isabella Mueller; James Talks
Journal:  Eye (Lond)       Date:  2022-01-28       Impact factor: 4.456

Review 5.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

Review 6.  The past, present and future management of sickle cell retinopathy within an African context.

Authors:  Kwesi Nyan Amissah-Arthur; Evelyn Mensah
Journal:  Eye (Lond)       Date:  2018-07-10       Impact factor: 3.775

Review 7.  Sickle cell retinopathy: improving care with a multidisciplinary approach.

Authors:  Farid Menaa; Barkat Ali Khan; Bushra Uzair; Abder Menaa
Journal:  J Multidiscip Healthc       Date:  2017-08-30

Review 8.  Surgical and Medical Perioperative Management of Sickle Cell Retinopathy: A Literature Review.

Authors:  Harrish Nithianandan; Jayanth Sridhar
Journal:  Int Ophthalmol Clin       Date:  2020

Review 9.  [Maculopathy in sickle cell disease].

Authors:  Isabel Bachmeier; Christiane Blecha; Jürgen Föll; Daniel Wolff; Herbert Jägle
Journal:  Ophthalmologe       Date:  2021-01-27       Impact factor: 1.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.